Table 5.
Responses by tumor histology.a
| Tumor type, n (%) | Responders | ||||||
|---|---|---|---|---|---|---|---|
|
A
(n = 5) |
B
(n = 5) |
C
(n = 3) |
D
(n = 3) |
E
(n = 2) |
F
(n = 3) |
G
(n = 1) |
|
| Breast cancer | 1 (20.0) | 1 (50.0) | |||||
| Colorectal cancer | 4 (80.0) | ||||||
| Esophageal cancer | 1 (20.0) | ||||||
| Gallbladder cancer | 1 (20.0) | 1 (33.3) | |||||
| Gastric cancer | 1 (50.0) | ||||||
| Mesothelioma | 1 (33.3) | 1 (33.3) | |||||
| Nasopharyngeal cancer | 1 (33.3) | ||||||
| Non–small cell lung cancer | 2 (66.7) | 1 (33.3) | |||||
| Ovarian cancer | 1 (33.3) | 1 (33.3) | |||||
| Pancreatic cancer | 3 (60.0) | ||||||
| Mucoepidermoid carcinoma | 1 (100.0) | ||||||
Treatment group A, mFOLFOX6 (oxaliplatin, leucovorin calcium [folinic acid], and 5-fluorouracil); treatment group B, nanoparticle albumin-bound (nab)-paclitaxel and gemcitabine; treatment group C, paclitaxel and carboplatin; treatment group D, pemetrexed and platinum agent; treatment group E, cyclophosphamide; treatment group F, gemcitabine and platinum agent; treatment group G, 5-fluorouracil and platinum agent.
With the exception of one patient with non–small cell lung cancer in treatment group C who developed a complete response, all other responses were partial responses.